Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
HYPD
Strong SellSinkerHyperion DeFi, Inc. · Healthcare · United States · $51M · Avg Vol: $2M/d
COMPANY DESCRIPTION
Hyperion DeFi, Inc., a DeFi company, engages in building on Hyperliquid. It operates through two segments: Ophthalmic Technology and Digital Assets. The company focuses on the long-term strategic treasury of HYPE tokens to provide simplified exposure to the Hyperliquid blockchain ecosystem.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 3.8K | 57.3K | 0.8M | 1365.6% | 1.4M | 1.7M | 113.2% |
| EPS | -1.96 | -1.95 | -5.80 | -9.40 | — | -3.86 | — | — |
| Shares | 15.5M | 15.5M | 15.5M | 8.7M | -44.1% | — | — | — |
| Debt | 10.1M | 16.1M | 11.2M | 8.5M | -5.6% | 8.9M | — | — |
| Equity | 17.2M | 9.0M | -13.1M | 41.1M | 33.6% | — | — | — |
| Op CF | -25.1M | -23.8M | -30.1M | -14.8M | — | -14.0M | — | — |
| Inv CF | -0.9M | -4.0M | -0.2M | -72.0M | — | — | — | — |
| Fin CF | 21.5M | 19.8M | 17.6M | 91.0M | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of HYPD are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| HYPD | Hyperion DeFi, Inc.(you) | $51M | 16 | Strong Sell |
| ELOX | Eloxx Pharmaceuticals, Inc. | $52M | 15 | Strong Sell |
| NTRB | Nutriband Inc. | $54M | 17 | Strong Sell |
| IMA | ImageneBio, Inc. | $61M | 15 | Strong Sell |
| PMVP | PMV Pharmaceuticals, Inc. | $65M | 16 | Strong Sell |
| TIL | Instil Bio, Inc. | $51M | 10 | Strong Sell |
| INKT | MiNK Therapeutics, Inc. | $58M | 12 | Strong Sell |
| SER | Serina Therapeutics, Inc. | $62M | 13 | Strong Sell |
| 4875.T | MediciNova, Inc. | $70M | 17 | Strong Sell |
| MCRB | Seres Therapeutics, Inc. | $51M | 8 | Strong Sell |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.1%